M
María Jesús Téllez
Researcher at Hospital Clínico San Carlos
Publications - 33
Citations - 1028
María Jesús Téllez is an academic researcher from Hospital Clínico San Carlos. The author has contributed to research in topics: Hepatitis C & Hepatitis C virus. The author has an hindex of 16, co-authored 31 publications receiving 869 citations.
Papers
More filters
Journal ArticleDOI
Sustained Virological Response to Interferon Plus Ribavirin Reduces Non-Liver-Related Mortality in Patients Coinfected With HIV and Hepatitis C Virus
Juan Berenguer,Elena Urbaneja Rodríguez,Pilar Miralles,Miguel A. Von Wichmann,José López-Aldeguer,Josep Mallolas,María José Galindo,Eva Van den Eynde,María Jesús Téllez,Carmen Quereda,Antoni Jou,José Sanz,Carlos Barros,Ignacio Santos,Federico Pulido,Josep M. Guardiola,Enrique Ortega,Rafael Rubio,Juan J. Jusdado,María Luisa Montes,Gabriel Gaspar,Herminia Esteban,José María Bellón,Juan González-García +23 more
TL;DR: The findings suggest that eradication of HCV after therapy with interferon plus ribavirin in HIV/HCV-coinfected patients is associated not only with a reduction in liver-related events but also with a reduced in HIV progression and mortality not related to liver disease.
Journal ArticleDOI
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.
Federico Pulido,Esteban Ribera,María Lagarde,Ignacio Pérez-Valero,Rosario Palacios,José Antonio Iribarren,Antoni Payeras,Pere Domingo,José Sanz,Miguel Cervero,Adrian Curran,Francisco J Rodríguez-Gómez,María Jesús Téllez,Pablo Ryan,Pilar Barrufet,Hernando Knobel,Antonio Rivero,Belén Alejos,María Yllescas,Jose R. Arribas +19 more
TL;DR: Dual therapy with darunavir/ritonavir and lamivudine demonstrated noninferior therapeutic efficacy and similar tolerability compared to triple therapy.
Journal ArticleDOI
Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations.
Vincent Soriano,J. M. Miró,Javier García-Samaniego,Julián Torre-Cisneros,Marina Núñez,J del Romero,Luz Martín-Carbonero,Jesús Castilla,José Antonio Iribarren,Carmen Quereda,M. Santín,J. González,Jose R. Arribas,Iria Santos,José Hernández-Quero,Enrique Ortega,Victor Asensi,M. A. del Pozo,Juan Berenguer,Cristina Tural,B Clotet,Manuel Leal,José Mallolas,José-María Sánchez-Tapias,Sonia Moreno,José M. Gatell,María Jesús Téllez,Rafael M. Rubio,E. Ledesma,Pere Domingo,Pablo Barreiro,José Pedreira,Miriam Romero,Juan González-Lahoz,Eduardo Lissen +34 more
TL;DR: These guidelines represent a comprehensive and updated overview on the management of hepatitis B and C in HIV‐infected patients and are based on a panel of Spanish experts in the field.
Journal ArticleDOI
Sexualized Drug Use (Chemsex) Is Associated with High-Risk Sexual Behaviors and Sexually Transmitted Infections in HIV-Positive Men Who Have Sex with Men: Data from the U-SEX GESIDA 9416 Study.
Alicia González-Baeza,Helen Dolengevich-Segal,Ignacio Pérez-Valero,Alfonso Cabello,María Jesús Téllez,José Sanz,Leire Pérez-Latorre,Jose I Bernardino,Jesús Troya,Sara De la Fuente,Otilia Bisbal,Ignacio Santos,Sari Arponen,Víctor Hontañón,José L. Casado,Pablo Ryan +15 more
TL;DR: The prevalence of SDU and associated factors in a sample of HIV‐positive men who have sex with men (MSM) in Spain and a clear association between SDU, high‐risk sexual behaviors, and STI including hepatitis C is found.
Journal ArticleDOI
Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids.
Pablo Barreiro,Vincent Soriano,Esperanza Casas,Vicente Estrada,María Jesús Téllez,Richard M. W. Hoetelmans,Daniel González de Requena,Inmaculada Jiménez-Nácher,Juan González-Lahoz +8 more
TL;DR: The incidence of rash complicating the first few weeks of treatment with NVP can be diminished by adding corticosteroids for 2 weeks to the standard recommendation, or by using a slowly escalating dose, which is proven to be pharmacokinetically safe.